Preservative-free preparation may improve adherence

Article

Tafluprost 0.0015% is safe, effective and well-tolerated in routine clinical practice

To date, prostaglandin analogues (PGAs) have become the most common medical treatment worldwide to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. PGAs have a strong, sustained and stable IOPlowering effect and a generally well tolerated systemic safety profile.

Tafluprost 0.0015% is the first and only PGA that is available in a preservative-free formulation. We evaluated the efficacy, local tolerability and safety of preservative-free tafluprost 0.0015% (Taflotan) in a routine clinical setting.1

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.